智通财经网·2025-10-24 13:32Core Viewpoint - Eli Lilly (LLY.US) announced plans to acquire gene therapy company Adverum Biotechnologies (ADVM.US) and its lead gene therapy candidate Ixo-vec, with the acquisition expected to enhance its capabilities in gene therapy for age-related diseases [1] Group 1: Acquisition Details - Eli Lilly will initiate a tender offer to acquire all outstanding shares of Adverum at a price of $3.56 per share [1] - The agreement includes a contingent value right (CVR) that could provide an additional $8.91 per share if specific milestones are met, bringing the total potential value to $12.47 per share [1] - The acquisition is expected to be completed in the fourth quarter of 2025, subject to customary closing conditions [1] Group 2: Strategic Rationale - Adverum focuses on developing intravitreal single-dose gene therapies aimed at restoring vision and preventing blindness [1] - The core product candidate, Ixo-vec, is a gene therapy for treating wet age-related macular degeneration (wAMD) [1] - The acquisition is intended to combine Eli Lilly's gene drug development capabilities with Adverum's technical expertise in ophthalmic gene therapies, expanding the potential of gene therapy in alleviating age-related disease burdens [1]